NVIDIA BioNeMo Locks In Pharma Partnerships as Novo Nordisk Outsources Parkinson's Therapy to AI Specialist
NVIDIA's BioNeMo platform has secured anchor partnerships with Thermo Fisher and Eli Lilly, positioning it as the dominant infrastructure layer for AI-driven drug discovery. Novo Nordisk, whose shares gained 24.9% over 30 days on strong Q1 2026 results, simultaneously licensed its Parkinson's cell therapy program to AI-native firm Cellular Intelligence while shutting its internal unit. A wave of new foundation model platforms from biotechs signals the sector is moving from infrastructure buildou
Salvado•